Fosun Pharma May Enter $4 Billion Bidding War For Germany's STADA Arzneimittel

Shanghai Fosun Pharma is said to be contemplating a bid for Germany's Stada Arzneimittel, a well established generic drug company. Stada has already received $3.8 billion qualifying bids from two private equity companies, but bidding is expected to get serious over the next month. Stada predicted it would produce 2017 EBITDA of $470 million on revenues of $2.5 billion. To make its offer, Fosun may team up with CVC Capital Partners, a global PE firm headquartered in Luxembourg. Or, Fosun may make the bid alone and seek partners later.